• Journal of Microbiology and Biotechnology
• /
• 제29권4호
• /
• pp.651-657
• /
• 2019

Although smallpox was eradicated in 1980, it is still considered a potential agent of biowarfare and bioterrorism. Smallpox has the potential for high mortality rates along with a major public health impact, eventually causing public panic and social disruption. Passive administration of neutralizing monoclonal antibodies (mAbs) is an effective intervention for various adverse reactions caused by vaccination and the unpredictable nature of emerging and bioterrorist-related infections. Currently, vaccinia immune globulin (VIG) is manufactured from vaccinia vaccine-boosted plasma; however, this production method is not ideal because of its limited availability, low specific activity, and risk of contamination with blood-borne infectious agents. To overcome the limitations of VIG production from human plasma, we isolated two human single-chain variable fragments (scFvs), (SC34 and SC212), bound to vaccinia virus (VACV), from a scFv phage library constructed from the B cells of VACV vaccine-boosted volunteers. The scFvs were converted to human IgG1 (VC34 and VC212). These two anti-VACV mAbs were produced in Chinese Hamster Ovary (CHO) DG44 cells. The binding affinities of VC34 and VC212 were estimated by competition ELISA to $IC_{50}$ values of $2{\mu}g/ml$ (13.33 nM) and $22{\mu}g/ml$ (146.67 nM), respectively. Only the VC212 mAb was proven to neutralize the VACV, as evidenced by the plaque reduction neutralization test (PRNT) result with a $PRNT_{50}$ of ~0.16 mg/ml (${\sim}1.07{\mu}M$). This VC212 could serve as a valuable starting material for further development of VACV-neutralizing human immunoglobulin for a prophylactic measure against post-vaccination complications and for post-exposure treatment against smallpox.

• Korean Journal of Radiology
• /
• 제21권4호
• /
• pp.422-430
• /
• 2020

The Korean Society of Urogenital Radiology (KSUR) aimed to present a consensus statement for patient preparation, standard technique, and pain management in relation to transrectal ultrasound-guided prostate biopsy (TRUS-Bx) to reduce the variability in TRUS-Bx methodologies and suggest a nationwide guideline. The KSUR guideline development subcommittee constructed questionnaires assessing prebiopsy anticoagulation, the cleansing enema, antimicrobial prophylaxis, local anesthesia methods such as periprostatic neurovascular bundle block (PNB) or intrarectal lidocaine gel application (IRLA), opioid usage, and the number of biopsy cores and length and diameter of the biopsy needle. The survey was conducted using an Internet-based platform, and responses were solicited from the 90 members registered on the KSUR mailing list as of 2018. A comprehensive search of relevant literature from Medline database was conducted. The strength of each recommendation was graded on the basis of the level of evidence. Among the 90 registered members, 29 doctors (32.2%) responded to this online survey. Most KSUR members stopped anticoagulants (100%) and antiplatelets (76%) one week before the procedure. All respondents performed a cleansing enema before TRUS-Bx. Approximately 86% of respondents administered prophylactic antibiotics before TRUS-Bx. The most frequently used antibiotics were third-generation cephalosporins. PNB was the most widely used pain control method, followed by a combination of PNB plus IRLA. Opioids were rarely used (6.8%), and they were used only as an adjunctive pain management approach during TRUS-Bx. The KSUR members mainly chose the 12-core biopsy method (89.7%) and 18G 16-mm or 22-mm (96.5%) needles. The KSUR recommends the 12-core biopsy scheme with PNB with or without IRLA as the standard protocol for TRUS-Bx. Anticoagulants and antiplatelet agents should be discontinued at least 5 days prior to the procedure, and antibiotic prophylaxis is highly recommended to prevent infectious complications. Glycerin cleansing enemas and administration of opioid analogues before the procedure could be helpful in some situations. The choice of biopsy needle is dependent on the practitioners' situation and preferences.

• Parasites, Hosts and Diseases
• /
• 제28권4호
• /
• pp.241-252
• /
• 1990

장포자충(Thelohanellus kitauei) 포자의 극사탈출 여부를 생사 각정 기준으로 하여 물리 화학적 요인이 포자의 활성 및 생존에 미치는 영향에 대하여 관찰하였다. 신선 포자를 0.45% 및 0.9% 생리식염수와 증류수에 현학시켜 $5^{\circ}C$ 또는 $28^{\circ}C$에 단기간 보존하면 3일까지, Tyrode액에 철 탁시켜 $-70^{\circ}C$에 단기간 냉동 보존하면 8일까지 극사탈출률이 상승하였다. 신선 포자를 0,45%생리 식염수에 현탁시켜 $5^{\circ}C$에 장기간 보존하면 1,270일간 생존할 수 있을 것으로 추정되며, 증류수에 현탁시켜 $28^{\circ}C$에 보존하면 152일간 밖에 생존하지 않으나, Tyrode액에 현탁시켜 $-70^{\circ}C$에 법통 보존하면 750일 후에도 냉동 초기와 거의 같은 패턴으로 생존하는 것으로 나타났다. 한편, 신선 효 자를 Tyrode액에 현탁, 냉동시킨 다음 $5^{\circ}C$의 조건 하에서 해동시킬 때 포자의 극사설출률이 가잔 높았다. 냉동 후 해동 포자에 열을 가하면 냉동기간이 길수록 극사탈출률이 약간 높아지는 경향이었으며 180일간 냉동례에 있어서 포자가 전부 사멸하는 한계점은 대체적으로 $60^{\circ}C$ 78.5시간, $70^{\circ}C$ 23.4시 간, $80^{\circ}C$ 189.1분 또는 $90^{\circ}C$ 10.5분이었다. 냉동 포자의 해동 후 사멸에 요하는 대체적인 기간도 냉동기간이 길수록 길며, 그 한계점은 20일간 냉동시 17.4일, 100일간 냉동 시 33.2일, 400일간 냉동시 37.8일이었다. 냉동 포자를 해동 후 자연건조시키면 냉동시간이 길수록 포자의 사멸에 요 하는 대체적인 기간도 길며, 그 한계점은 540일간 냉동시 23.5일, 160일간 냉동시 21.0일, 20일간 냉동시 14.4일이었다. 한편, 냉동 후 해동 포자에 l0W 자외선등을 조사하면 냉동시간이 길수록 빨리 사멸하며, 그 한계점은 100일간 냉동시 26.0시간, 300일간 냉동시 21.9시간, 540일간 냉동시 13.9시간이었다. 각종 소독제(1,000 ppm)가 200일간 냉동 후 해동 포자를 사멸시키는데 필요한 시 간은 산화칼슘 5.2분, 과망간뜬칼륨 10.4분, 말라카이트그린 27.8분, 포르말린 14.3시간의 순이었다. 그리고, 각종 항원충 및 둔진균제 중에서 ketoconazole, metronidazole, dapsone의 순으로 일시적인 극사탈출 억제 효과가 인정되었다. 이상의 실험 결과로 미루어 보아 장포자충증의 감염을 예방하기 위해서는 현시점에 있어서 양어장의 바닥을 콘크리트로 축달하여 완전 건조시킨 다음 산화칼슘을 철포하고 태양광선을 수일 간에 걸쳐 조사시키는 방법 밖에 없는 것으로 생각된다.